Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/884629/000119312513419835/d604304d10q.htm
November 2013
October 2013
October 2013
October 2013
October 2013
September 2013
September 2013
August 2013
August 2013
August 2013
Exhibit 99.1
NEWS RELEASE
CONTACTS: | Investors: | |
Lisa DeFrancesco | ||
(862) 261-7152 | ||
Media: | ||
Charlie Mayr | ||
(862) 261-8030 | ||
David Belian | ||
(862) 261-8141 |
Actavis Net Revenue Increases 57% to $2.01 Billion in Third Quarter 2013; Non-GAAP EPS Increases 55% to $2.09
- GAAP Earnings Per Share of $0.49 -
- 61% Increase in Adjusted EBITDA to $489 million -
- Company Updates 2013 Forecast, Provides Preliminary 2014 Outlook -
DUBLIN October 29, 2013 Actavis plc (NYSE: ACT) today reported net revenue increased 57 percent to $2.01 billion for Actavis, Inc.s third quarter 2013, compared to $1.29 billion in the third quarter 2012. On a non-GAAP basis, diluted earnings per share for the third quarter 2013 were $2.09, compared to $1.35 per diluted share in the third quarter 2012, an increase of 55 percent. GAAP earnings per diluted share for the third quarter 2013 were $0.49, compared to GAAP earnings per diluted share of $0.60 in the prior year period. These reported results exclude any results from Warner Chilcott plc, which Actavis plc acquired on October 1, 2013.
For the third quarter 2013, adjusted EBITDA increased 61 percent to $489.2 million, compared to $304.6 million for the third quarter 2012. Cash flow from operations for the third quarter of 2013 was $270.8 million and cash and marketable securities were $373.5 million as of September 30, 2013.
Double-digit revenue and earnings growth marked another exceptional quarter for Actavis, Inc., as we continue to accelerate our transformation into a global specialty pharmaceutical leader, said Paul Bisaro, Chairman and CEO of Actavis plc.
1
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/884629/000119312513419835/d604304d10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Actavis, Inc..
Actavis, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:
CIK: 884629
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-13-419835
Submitted to the SEC: Thu Oct 31 2013 9:17:27 AM EST
Accepted by the SEC: Thu Oct 31 2013
Period: Monday, September 30, 2013
Industry: Pharmaceutical Preparations